Meta-analysis fever in the wake of CARAVAGGIO

The CARAVAGGIO clinical trial has clearly been a landmark study that established the important role for direct oral anticoagulants (DOACs), especially apixaban as a treatment for venous thromboembolism (VTE) in cancer [1]. The study clearly showed that apixaban was non-inferior to subcutaneous dalteparin for the treatment of cancer associated VTE without an increased risk of major bleeding.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Editorial Source Type: research